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INTRODUCTION
Nociceptive stimulation cause hyper- excitability 
with the activation of N-methyl-D-aspartate 
(NMDA) receptor, a process that involved in acute 
pain pathophysiology. Ketamine, a  non-competitive 
NMDA antagonist, used in sub-anesthetic dose can 
result in specific NMDA blockage and modulate 
central sensitization hence cause anti  hyper-algesic 
effect.1
Ketamine has been used as an intravenous 
anesthetic. Ketamine has also been used as anal-
gesic for acute and chronic pain in sub-anesthetic 
dose. Ketamine has several benefits as an anal-
gesic. Ketamine does not depress cardiovascular 
function, protective larynx reflects, less depress 
ventilation compare to opioid, and reduce airway 
resistance. Thus, ketamine has significant role in 
postoperative pain management by reducing the 
total opioid needed, possible side effects, and giving 
hemodynamic and respiratory stability.2
Ketamine also has immune modulator prop-
erty. Ketamine can prevent exacerbation and 
local inflammation expansion without disturbing 
inflammation resolution. Immune cell produc-
ing inflammation cytokine does not affected by 
ketamine if there is no inflammation stimulus. 
The immune regulation effect clearly can be seen 
if ketamine is used before the inflammation. This is 
one of reasons that ketamine is commonly used for 
induction before surgery.3
Small dose ketamine given before noxious stim-
ulus can have benefit as well by preventing central 
sensitization which lead in decreasing the need for 
post operative analgesic.4
NMDA (N-methyl-D-aspartate) Antagonist 
Receptor
Inotropic receptor divided into three subtypes 
based on the action of selective agonist: α-ami-
no-3-hidroxy-5-methylisoxasole-4-propionic 
acid (AMPA), kainic acid (KA), and N-methyl-D-
aspartate (NMDA). Among those, NMDA receptor 
gets special consideration because its role in sympa-
thetic stimulation transmission, plasticity, and 
central nervous system (CNS) neurodegenerative. 
This receptor is located in all neurons.5
NMDA (N-methyl-D-aspartate) receptor antag-
onist administered as an additional medication 
pain management. Receptor N-methyl-D Aspartate 
receptors are ligand-gated ion channel which 
allows the entry of calcium, sodium, potassium 
into cells. The receptor is activated by glutamate 
and glycine and is not opened when the membrane 
resting potential. Glutamate is the major excitatory 
neurotransmitter in the central nervous system has 
a significant role in the modulation of pain at the 
spinal cord level. This role in particular in sensiti-
zation of nociceptors after exposure to pain stimu-
lation that increases the magnitude and duration of 
neurogenic responses to pain, even after the initials 
of a peripheral has been discontinued. These drugs 
carry antinociception effect by inhibiting central 
sensitization to pain stimulation.6
Ketamine
Ketamine is a phencyclidine derivative (anesthetic 
used in veterinary medicine), noncompetitive 
NMDA receptor antagonist. Ketamine is used for 
intravenous induction of anesthesia in the world, 
especially in circumstances in which sympathetic 
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ABSTRACT
Ketamine binds non-competitive against a phencyclidine receptors 
bound N-methyl-D-aspartate (NMDA), a receptor that is involved in the 
pathophysiology of acute pain. Ketamine has been used as an intravenous 
anesthesia, analgesia for acute and chronic pain at a dose of subanaesthetic. 
Ketamine is a dissociative anesthetic produces a state with a characteristic 
strong analgesia, amnesia, and catalepsy. Dissociative components 
resulting from the effect on the limbic system and talamoneokortikal. Low-
dose ketamine as known as analgesia dose ketamine or subanestesia dose 
is 0.2 to 0.75 mg / kg IV. At low doses, ketamine does not increase the effect 
psychomimetic like dissociation or deep sedation. The combination with 
midazolam provides satisfactory sedation, amnesia and analgesia without 
significant cardiovascular depression.
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stimulation is needed (hypovolemia, trauma). 
When intravenous access is not available, it can be 
used by intramuscular ketamine for induction in 
pediatric or adult who is not cooperative. Ketamine 
can be combined with other drugs (such as propo-
fol or midazolam) in a small dose bolus or infu-
sion for sedation during peripheral nerve blocks, 
endoscopy, and others. sub-anesthetic doses of 
ketamine can cause hallucinations (depending on 
dose), though in daily practice this effect is not so 
noticeable because of the provision of a combina-
tion with midazolam (or similar drugs) for amnesia 
and sedation.7
Ketamine is a dissociative anesthetic drug that 
produces, which is then marked by the dissociation 
of EEG between thalamocortical and limbic system. 
Dissociation anesthesia resembles cataleptic condi-
tion where the eyes are still open and slow nystag-
mus. Patients unable to communicate, even though 
he appeared conscious. Reflexes still maintained 
as the corneal reflex, cough reflex and swallowing 
reflex, but all these reflexes should not be consid-
ered as a protection against the airway. Hypertonus 
level variations and certain skeletal muscle move-
ments often occur and are not dependent on the 
surgical stimulation.8
Chemical structure
Ketamine, 2-(o-chlorophenyl) -2- (methylamino) 
-cyclohexanonehydrochloride, a arylcycloalkyl-
amine which is structurally related to phencyclidine 
(PCP) and cyclohexamine. Ketamine hydrochloride 
is an water-soluble molecules, with a molecular 
weight of 238 and a pKa of 7.5. Although soluble 
in water, soluble in fat ten times compared with 
thiopentone, so quickly distributed to many organs, 
including the brain and heart, and then redistrib-
uted to organs with less perfusion. The existence 
of asymmetric carbon atoms produce two opti-
cal isomers of ketamine namely S (+) ketamine 
and R  (-) ketamine. Commercial dosage forms of 
racemic ketamine form containing both enantio-
mers in equal concentrations. Each enantiomer 
has a different potential. S (+) ketamine analgesia 
stronger, faster metabolism and recovery, lack of 
secretion of saliva and a low incidence of emergence 
reaction or nightmares / hallucinations than the 
R (+) ketamin.9
Mechanism of action
Ketamine binds non-competitively against a phen-
cyclidine receptors bound N-methyl-D-aspartate 
(NMDA), a subtype of glutamate receptors, which 
are located in the ion channel. Ketamine inhibits 
the transmembrane ion flow. NMDA receptor is 
a receptor calcium channels. Endogenous agonist 
of the receptors are excitatory neurotransmitters 
such as glutamic acid, aspartic acid, and glycine. 
Activation of the receptor results in the opening of 
the ion channel and depolarization of the neuron. 
NMDA receptors are involved in the sensory input 
at the spinal level, thalamic, limbic and cortical 
bone. Ketamine inhibit or interfere with the sensory 
input to the central higher than the central nervous 
system, where there is an emotional response to the 
stimulus and the place for learning and memory. 
Ketamine inhibits activation of NMDA receptors 
by glutamate, reducing the release of glutamate in 
presynaptic and enhance the effects of the inhibi-
tory neurotransmitter GABA.10
Ketamine also interact with mu receptors, delta 
and kappa opioid. Effects of ketamine analgesia 
may be caused by activation of this receptor in the 
central and spinal.9 
Some effects of ketamine can be caused by work 
on the catecholamine system, by increasing dopa-
mine activity. Dopaminergic effects may be related 
to the euphoric effects, addiction and psychotomi-
metic of ketamine. The work of ketamine is also 
caused by the effect of adrenergic agonists on the 
receptor α and β, antagonistic effect on muscarinic 
receptors in the central nervous system, and the 
effects on receptor agonists σ.10
PHAMACOKINETIC
a) Absorption 
Ketamine can be used via the oral, nasal, rectal, 
subcutaneous, and epidural, even though in daily 
practice ketamine used intravenously or intra-
muscularly. Peak plasma levels achieved within 
5-15 minutes after intramuscular injection, in 
1 min after intravenous injection, and 30 minutes 
after oral administration. Absorption via the 
rectal ketamine in pediatric in a study can reach 
45  minutes. Norketamine metabolite plasma 
concentrations higher than ketamine alone after 
oral administration.5Picture 1 Ketamine structure.
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b) Distribution 
Ketamine is more soluble in fat and less protein 
bound (12%) compared to thiopental, which facil-
itates the transfer through the blood-brain barrier. 
Ketamine is distributed to a network with such high 
perfusion of the brain to reach the level of 4-5x 
higher than plasma. These characteristics increase 
cerebral blood flow and cardiac output, resulting 
in a rapid uptake by the brain and subsequent 
redistribution (half distribution of 10-15 minutes). 
Employment effects of ketamine disappeared with 
redistribution from rich network of blood vessels to 
less tissue blood vessels. Awakening due to redistri-
bution of the brain compartment perifer.6
c) Metabolism 
Ketamine is metabolized in the liver into several 
metabolites, one of which is norketamin which 
retains the anesthetic activity. The most important 
metabolic pathways involving N-demethylation by 
cytochrome p450 into norketamin. Norketamin 
then hydroxylated and conjugated into water 
soluble components that will be excreted in the 
urine. Uptake liver (hepatic extraction ratio of 
0.9) describes the elimination half-life of ketamine 
relatively short (1-2 hours) and depends on the 
hepatic blood flow changes. Co-administration 
with  diazepam can extend the half-life of ketamine 
and its metabolite.6
d) Excretion 
Ketamine metabolic end products excreted through 
the kidneys, with a small percentage is found in 
the urine in the form intact. Elimination half-life 
2 hours, which is due to a combination of rapid 
clearance and volume of distribution were great. It 
has been reported in pediatric research studies that 
the elimination of ketamine two times faster than 
adult.11,12
PHARMACODYNAMIC
a) Central Nervous System. 
Ketamine produces a state described as a disso-
ciative anesthetic with characteristics of strong 
analgesia, amnesia, and catalepsy. The dissosiative 
components resulting from the effect on the limbic 
system and thalamoneocortical. In this condition 
it is said that the brain fails transduction afferent 
impulses properly because of interference with the 
normal communication between the sensory and 
cortical association areas. The result resembles 
catalepsy that both eyes remain open with nystag-
mus, and corneal reflexes are intact. Patients are 
 generally non-communicative although they are 
awake. Varying degrees of skeletal muscle hyper-
tonus may occur. Involuntary skeletal muscle 
contraction can occur during surgery. The ketamine 
users has its own difficulties in assessing the level 
of sedation or anesthesia because it cannot use the 
sign of eyes movement, muscle tone or movement 
of the patient as an indicator. Effects of ketamine 
on the above characteristics are not consistent with 
the classic signs of anesthesia. Ketamine interacts 
with more than one type of receptors to produce a 
variety of effect.11
Some part of analgesia effect are mediated by 
opioid receptors in the brain, spinal and peripheral. 
Ketamine also interact with opioid receptors sigma / 
phenyclyclinidine binding sites. Sigma component 
may mediate dysphoria generated by ketamine.7
Place of work involving NMDA receptor 
ketamine (N-methyl-D-aspartate). This receptor 
plays a major role in the transmission of sensory 
information and mediates the excitation of neurons 
in the central nervous after the arrangement of 
interacting with excitatory neurotransmitter. 
Inhibition of NMDA gives effect of catalepsy.7
Ketamine produces anti-nociceptive effect 
through interactions with mu receptors on the 
spine, antagonis NMDA receptors, and activation 
of descending mono-aminergic pain inhibitory 
pathways. Affinity in NMDA receptors greater 
than against mu receptors, and is much larger than 
the monoamnine receptor or other non-NMDA 
receptors (e.g. sigma receptor and acetylcholines-
terase), which causes the smaller dose of ketamine 
are increasingly selective NMDA receptors interact 
with ketamine.6
Potential effects of ketamine disabling muscle 
depends in large doses. This mechanism may 
involve cholinergic muscarinic receptors. Ketamine 
can turn on a wave of epilepticform in patients with 
convulsion disorders.11
Emergence is the most frequent side effects 
reported. The reaction was described as a sense of 
drift, dream that seem obvious, hallucinations, and 
delirium. To this effect the incidence ranges from 
5-30%. Benzodiazepine uses can reduce this effect.12
Ketamine dogma against the order of the central 
nervous causes an increase in the consumption 
of oxygen on cerebral blood flow, cerebral, and 
increased intracranial pressure. Ketamine vaso-
dilatory blood vessels of the brain that causes 
an increase in cerebral blood flow by as much as 
62-80%. This effect is reduced when the diazepam, 
midazolam, or tiopental given before ketamine. 
These effects hinder the use of ketamine in 
patients with intracranial space occupying lesion 
in or head trauma. The publication now offers 
convincing evidence that when combined with 
benzodiazepines (or another agent who works at 
the GABA receptors), and ventilation control, but 
not with nitrous oxide, ketamine does not increase 
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intracranial pressure. Psychotomimetic side effects 
(like a bad dream and delirium) when emergence is 
rare in pediatric patients or those with profopol or 
benzodiazepine.12
b) Respiration 
In patients with spontaneous breath,  dispensing 
other general anesthesia can cause a rapid 
decrease  in FRC (Functional Residual Capacity). 
With the decrease in lung volume during expi-
ration, the small and thin-walled airway on the 
dependent lung has a tendency to collapse. The 
volume in which the airway closes so-called  closing 
capacity. The effect of maintaining the FRC is guar-
antee the openness of the dependent part remains 
in the lung. This is important especially for pedi-
atric, where closing capacity slightly less to the 
FRC than adults. In pediatrics, a small decrease of 
FRC may lead to closure of the airway for normal 
breathing, which can cause ventilation perfusion 
abnormalities were clinically shown as decreased 
oxygen saturation. Ketamin is considered unique 
in that it can sustain the FRC during induction of 
anesthesia.12 During the administration of ketamine 
in patients breathing spontaneously, minute venti-
lation is maintained almost the same as the patient 
is awake. Minimal changes occurred in the absence 
of gas exchange and the incidence of atelectasis and 
shunting. This is because the skeletal muscle tone is 
maintained during the administration of ketamine 
(unlike in patients with volatile anesthetics) then 
atelectasis, ventilation-perfusion changes, and the 
FRC did not happen. Breathing is affected mini-
mally by ketamine. Ketamine has other beneficial 
effects, including increased lung expansion and 
decreases airway resistance. The working mecha-
nism of these effects has yet to be fully understood. 
Bronchodilatation is the result of inhibition of 
calcium channels by ketamine. Racemic ketamine is 
a poten bronchodilator, making it a good induction 
agent for asthma patients; however, S (+) ketamine 
has a minimal bronchodilator effect ketamine by 
continuous infusion is used as an asthma therapy 
that is unresponsive to conventional approaches. 
Airway reflexes preserved intact, but the partial 
airway obstruction may occur. Hypersalivation 
caused by ketamine may be reduced by adminis-
tering anticholinergic agents such as premedication 
glycopyrrolate and atropine.11,12
c) Cardiovascular
In contrast with other anesthetic agents, ketamine 
increases blood pressure, heart rate, and cardiac 
output, especially after rapid bolus injection. These 
indirect effects on cardiovascular due to central 
stimulation of the sympathetic nervous system and 
norepinephrine reuptake inhibition after being 
released at the nerve terminals. Ketamine depress 
myocardial contractility, but this effect was offset 
by sympathetic stimulation. In addition, the ability 
of ketamine improves concentration inhibits the 
neuronal reuptake of catecholamines to also cover 
the negative inotropic effect of ketamine. Therefore, 
high doses of ketamine bolus injection should be 
administered with caution in patients with coronary 
heart disease, uncontrolled hypertension, conges-
tive heart disease, blood vessel or aneurysm.7,12
These sympathomimetic effects will increase 
myocardial oxygen demand, therefore, ketamine 
is contraindicated in patients with ischemic heart 
disorders. Cardiac dysrhythmia is rare in the 
administration of ketamine, although studies in 
animals declared ketamine sensitize the myocar-
dium causing effects such dysrhytmogenic with 
epinephrine. Based on cardiovascular effects, 
especially the ability to maintain blood pressure, 
ketamine administration is indicated in pediatric 
congenital cyanotic heart disease, patients with 
hypovolemic, and cardiogenic shock. In pediatric 
with cyanotic congenital heart disease, the amount 
of oxygen that can be taken by the lungs depends on 
pulmonary blood flow. Ketamine is used to lower 
the right to left shunt, which will maximize blood 
flow and pulmonary arterial pressure of oxygen.12
d) Temperature 
In the past, there is concern that ketamine trigger 
malignant hyperthermia. This is because ketamine 
can increase catecholamine circulation, which is 
regarded as the originator of malignant hyper-
thermia. Nevertheless ketamine does not trigger 
malignant hyperthermia in a study using a pig. This 
is reinforced by the recommendation of Malignant 
Hyperthermia Association of the United States.12
e) Inflammatory
Inflammatory reaction aims to maintain body 
homeostasis. The goal is to fight infection and 
tissue injury. This is based on various stages of 
the reaction, each under the influence of a posi-
tive control (proinflammatory) or negative (anti- 
inflammatory). Inflammatory reaction occurs 
when the host immune cells such as macrophages, 
fibroblasts, mast cells, and dendritic cells, or leuko-
cytes circulating detect pathogens or cell damage. 
The mechanism involves the detection of patterns 
Expressed surface receptor recognition that Toll 
receptors (TLRs), which play a major role in activat-
ing the immune cells of the host. As a consequence 
of this reaction, a transcription factor (NF-κB, 
AP1, CREB, C / EBP, and IRF) will be  activated. 
Leukocytes that are in circulation will be directed to 
this area. The mediator histamine, prostaglandins 
and NO will cause local vasodilation. Under the 
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influence of histamine and leukotrienes, vascular 
permeability increases. Immune cells that are on 
the site of infection or injury will get rid of foreign 
objects with phagocytosis. At the same time it will 
release cytokines and other mediators begin the 
healing process.3,13 
Regulation of inflammatory reactions occur 
at the level of the peripheral and central level. At 
the peripheral level, anti-inflammatory cytokines 
(receptor antagonist IL-1, IL-4, IL-10, interferon 
alfa) will be released by immune cells that would 
antagonize the inflammatory reaction (IL-1, IL-6, 
TNF α) kill the inflammatory cells. Il-6 will stimu-
late production of CRP (C-Reactive Protein) in the 
liver by activating kinase pathway. At the central 
level, when there is inflammation of peripheral 
there will be communication between immune cells 
and the central nervous system. The central nervous 
system is informed that there is ‘something’ in the 
periphery. Then modulation the central nervous 
system inflammation that this reaction occurs only 
in the peripheral alone. This is expressed by the 
dominance of Th-2 (anti-inflammatory) to the Th-1 
(pro-inflammatory).3
Ketamine is said to affect inflammation. 
Ketamine significantly reduced the production 
of inflammatory cytokines without affecting 
the production of anti-inflammatory cytokines. 
Ketamine reduces exacerbation inflammatory reac-
tions and hastens the resolution of inflammation by 
helping the inflammatory cell apoptosis. Ketamine 
had no effect on immune cells that produce inflam-
matory cytokines when there are no inflammatory 
stimulus. This regulatory effect is more meaningful 
when ketamine administered before inflamma-
tion. This is also the reason why ketamine given at 
induction of anesthesia before surgery. Ketamine at 
a dose of 0.5 mg/kg increase the ratio of Th1 / Th2 
thus improving the patient’s immune function. In 
some studies, ketamine lowers TNF α, IL-6, IL-1 
and IL-8, which in turn provide results such as 
reducing the acidosis and improve cure rates.3
CLINICAL APPLICATIONS
Ketamine can be used for preoperative and intra-
operative sedation, balance anesthesia,  adjuvant 
regional anesthesia and postoperative analgesia. 
Ketamine is used for preoperative to reduce anxiety 
and facilitate the induction of general anesthesia. 
Intramuscular administration used in pediatrics. 
One study suggests intramuscular administra-
tion at a dose of 2 mg/kg resulted in rapid onset 
of dissociative effects begin at 2.7 minutes. Rectal 
administration at a dose of 10 mg/kg body weight 
for induction of general anesthesia preceded by 
premedication midazolam and atropine. Loss 
of consciousness occurs within 9-15 minutes. 
Ketamine has also been used for regional anesthesia 
and epidural.7
For sedation and analgesia, ketamine adminis-
tered at subanesthetic dose of 0.2 to 0.75 mg/kg intra-
venous continuous infusion of 5-20 mcg/kg/min, 
2-4 mg/kg intramuscularly. Ketamine’s effect 
of analgesia achieved in plasma concentrations 
of 100-150ng/ml. A study says that analgesia is 
achieved by administering ketamine 125-250 mcg/
kg. This dose is sufficient to achieve plasma concen-
trations of 100-150 ng/ml. Provision of ketamine 
50 mcg/kg did not provide sufficient analgesia, but 
enough to make the drowsiness, the lowest dose 
provides analgesia is 75 mcg/kg.14 Plasma concen-
trations can be achieved by a continuous infusion at 
a dose of 3-4 mcg/kg/min after the initial bolus and 
14 mcg/kg/min without loading dose.15 For general 
anesthesia, ketamine given at a dose of 1 to 4.5 mg/kg 
intravenously, 6.5-10 mg/kg intramuscularly.16
Subanesthetic Dose of Ketamine (Low Dose 
Ketamin)
Low-dose ketamine also known as analgesia dose 
or subanesthetic dose is 0.2 to 0.75 mg/kg IV. Other 
literature mentions doses of analgesia achieved 
at 0.2-0.5 mg/kg IV. The analgesic effect is more 
pronounced in visceral pain than somatic pain. 
Ketamine effect is caused by activity in the thala-
mus and the limbic system is responsible for the 
interpretation of pain. At doses of 0.25-0.5 mg/kg 
IV given after midazolam 0.07 to 0.15 mg/kg IV 
ketamine is said to provide a satisfactory sedation, 
amnesia, and analgesia without significant cardio-
vascular depression. The incidence of emergency, 
the side effects of ketamine does not increase with 
small doses of ketamine. At a dose of 0.15 to 1 mg/kg 
IV did not increase psychomimetic effects such as 
hallucinations or deep sedation. The addition of 
Table 1 Advantages and disadvantages of ketamine.6
Advantages Loss
Analgesia at doses subanaesthetic Emergence
Amnesia Cardiovascular stimulation
Maintaining FRC Minimal respiratory depression
Laryngeal reflexes are depressed minimally Hypersalivation
Rapid onset
Long predictable action
Non-toxic metabolite
Soluble in water
Stable in solution
No post-injection pain
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small doses of ketamine 0.5 mg/kg for induction 
propofol 1.5 mg/kg IV can reduce the incidence of 
desaturation and apnea.15
At a dose of 0.1-0.5 mg / kg IV ketamine provide 
satisfactory analgesia during surgery and the 
management of post-surgical pain, without any 
sedation or changes in hemodynamic and respira-
tory. Effects of nausea and vomiting are also much 
reduced at this dose.16
The use of low-dose ketamine with local anes-
thetic also has been widely applied with giving 
ketamine 0.05 mg/kg/hour IV infusion in addition 
to continuous epidural ropivacaine and morphine 
and obtained results that ketamine enhances the 
effects of ropivacaine-morphine analgesia and 
reduces pain post-thoracotomy.16
For the prevention of occurrence shivering in 
general anesthesia, ketamine prophylactic dose of 
0.5 mg/kg IV given 20 minutes before the oper-
ation is over, have proven effective in preventing 
postoperative shivering. In spinal anesthesia, 
ketamine 0.5  mg/kg IV or ketamine 0.25 mg/kg 
IV+midazolam 37.5 mcg/kg IV can prevent the 
incidence of shivering after administration of 15 mg 
of bupivacaine.10
Ketamine given before incision has an effect 
on postoperative pain and reduce the need for 
analgesics. Put pain impulses during surgery and 
postoperative causes continuous stimulation of 
C fibers nociceptors and causes the release of gluta-
mate. Glutamate is the primary neurotransmitter 
excitatory in the central nervous system which acti-
vates postsynaptic NMDA receptors. Activation of 
NMDA receptors contributes to processes such as 
wind-up pain and central sensitization. Activation 
of these receptors constantly plays a role in inflam-
matory and neuropathic pain process, which will 
lead to secondary hyperalgesia. Intervention anal-
gesic before the pain stimulation may inhibit sensi-
tization and reduce acute pain.4,17
The wind-up phenomenon is the basis of pre- 
emptive analgesia, which provides an analgesic before 
the onset of pain. By suppressing acute pain response 
as early as possible, pre-emptive analgesia may 
prevent or at least reduce the possibility of “wind-up”. 
Ideally, analgesics has begun before surgery.10 
DRUG INTERACTIONS
Ketamine interacts synergistically with the vola-
tile agent, propofol, benzodiazepines, and other 
agents mediated by GABA receptors. Diazepam 
and midazolam alter cardiac simultaneous effects 
of ketamine and diazepam extend the elimi-
nation half-life of ketamine. Nondepolarizing 
muscle relaxants are potentiated by ketamine. 
The combination of theophylline with ketamine 
may predispose patients to seizures. Halothane 
slows down distribution and inhibits the hepatic 
metabolism of ketamine, thus prolonging the effect 
of ketamine on the central nervous system. N2O 
reducing the dosage of ketamine and shorten recov-
ery time of ketamine.9 
CONCLUSION
Ketamine is a phencyclidine derivative (an anesthetic 
used in veterinary medicine), non- competitive 
NMDA receptor antagonist. The chemical struc-
ture of ketamine, 2- (o-chloro- cyclohexanone 
hydrochloride, an arylcycloalkylamine which is 
structurally related to phencyclidine (PCP) and 
cyclohexamine. Ketamine non- competitively binds 
against a phencyclidine receptors bound N-methyl-
D-aspartate (NMDA). Ketamine inhibits or inter-
feres the sensory input to the central higher than 
the central nervous system, as well as inhibiting the 
activation of NMDA receptors by glutamate, reduc-
ing the release of glutamate in presynaptic and 
enhance the effects of the inhibitory neurotrans-
mitter GABA. Ketamine also interacts with mu 
receptors, delta and kappa opioid.
Pharmacokinetics of ketamine is rapid onset, 
relatively short duration and high lipid solubility. 
Ketamine is not bound significantly in plasma 
and distributed quickly to the organs. Ketamine is 
metabolized in the liver by the hepatic microsomal 
enzymes through N-demethylation of ketamine by 
the cytochrome P-450 into nor ketamine (metab-
olite I), then hydroxylated become hydroxy-nor 
ketamine. This product is conjugated to glucuro-
nide derivatives that are soluble in water and are 
excreted in the urine.
Pharmacodynamics ketamine in the central 
nervous system, which produces a dissociative 
anesthesia state with characteristic strong analgesia, 
amnesia, and catalepsy. In the respiratory system 
can cause a rapid decrease in FRC (Functional 
Residual Capacity). In the cardiovascular system 
to stimulate the cardiovascular system ketamine 
causes an increase in blood pressure, cardiac output, 
heart rate, systemic vascular resistance, pulmonary 
artery pressure and pulmonary vascular resistance.
Ketamine can be used for preoperative and intra-
operative sedation, balanced anesthesia, regional 
anesthesia, spinal anesthesia and  postoperative 
analgesia. Also known as low-dose ketamine, 
ketamine analgesia dose or subanesthetic dose of 
0.2 to 0.75 mg/kg IV, provides satisfactory analge-
sia during surgery and the management of post- 
surgical pain, without any sedation or changes in 
hemodynamic and respiratory.
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Ketamine interacts synergistically with the vola-
tile agent, propofol, benzodiazepines, and agents 
mediated by GABA receptors other.
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